• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

5.260 -0.130 (-2.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 562,557
Open 5.360
Bid (Size) 5.270 (1)
Ask (Size) 5.350 (5)
Prev. Close 5.390
Today's Range 5.240 - 5.440
52wk Range 1.140 - 7.200
Shares Outstanding 58,576,350
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
October 10, 2025
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators. 
Via Benzinga
4 Biotech Stocks Seeing Explosive Momentum Gains
October 07, 2025
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be... 
Via Benzinga
Topics ETFs Stocks

Performance

YTD
+0.8%
+0.8%
1 Month
+7.3%
+7.3%
3 Month
-2.4%
-2.4%
6 Month
+134.8%
+134.8%
1 Year
-5.2%
-5.2%

More News

Read More
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 03, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
August 28, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
August 19, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 06, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
July 24, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
July 17, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
June 26, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
June 17, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
May 29, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
May 18, 2025
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
May 14, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
May 13, 2025
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
May 09, 2025
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
May 07, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 06, 2025
Via Benzinga
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
May 05, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap
May 05, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
May 05, 2025
From Pomerantz LLP
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
May 05, 2025
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
April 29, 2025
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm
April 28, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALDX
April 25, 2025
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
April 25, 2025
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Aldeyra Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aldeyra Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aldeyra Therapeutics, Inc. - Common Stock trade on?
Aldeyra Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock?
The ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock is ALDX on the Nasdaq Stock Market
What is the current price of Aldeyra Therapeutics, Inc. - Common Stock?
The current price of Aldeyra Therapeutics, Inc. - Common Stock is 5.260
When was Aldeyra Therapeutics, Inc. - Common Stock last traded?
The last trade of Aldeyra Therapeutics, Inc. - Common Stock was at 10/17/25 04:00 PM ET
What is the market capitalization of Aldeyra Therapeutics, Inc. - Common Stock?
The market capitalization of Aldeyra Therapeutics, Inc. - Common Stock is 308.11M
How many shares of Aldeyra Therapeutics, Inc. - Common Stock are outstanding?
Aldeyra Therapeutics, Inc. - Common Stock has 308M shares outstanding.
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap